Nutriband Inc. provided shareholders with an update following its 2026 Annual Shareholders Meeting, highlighting the appointment of two new directors and outlining key progress in the development of AVERSA Fentanyl. The company appointed Alessandro Puddu and Viorica Carlig to its board of directors during the meeting held on Jan. 24, 2026, in Orlando, Florida.
During 2025, Nutriband strengthened its exclusive partnership with Kindeva, a move critical for the commercial manufacturing scale-up of its lead product. The company also expanded global patent protection for its AVERSA technology, securing new patents in the United States and Macao. This expansion helps safeguard the proprietary abuse-deterrent technology designed to prevent misuse of transdermal patches containing drugs with abuse potential.
Nutriband engaged with the U.S. Food and Drug Administration through a Type C meeting, an important regulatory step that provides guidance on development plans. The company advanced branding initiatives for AVERSA Fentanyl, positioning the product for future market entry. The AVERSA technology can be incorporated into any transdermal patch to prevent abuse, misuse, diversion, and accidental exposure of drugs with abuse potential, addressing a significant public health concern surrounding opioid medications.
Looking ahead to 2026, Nutriband plans to advance toward a New Drug Application filing by extending patent protection potentially to 2046. The company will manufacture clinical supplies, file an Investigational New Drug application, and initiate a Human Abuse Liability clinical study. These steps represent critical milestones in the regulatory pathway for abuse-deterrent formulations.
The development of AVERSA Fentanyl carries implications for addressing the ongoing opioid crisis by providing healthcare providers with additional tools to mitigate abuse risks associated with fentanyl patches. Abuse-deterrent technologies represent an important area of pharmaceutical innovation, particularly for potent opioids that carry significant misuse potential. Successful development and regulatory approval could offer a new option for pain management with enhanced safety features.
For investors and stakeholders following the company's progress, the latest news and updates relating to NTRB are available in the company's newsroom at https://ibn.fm/NTRB. The broader biomedical and biotechnology community can access specialized communications through platforms like BioMedWire, which focuses on developments in biotechnology, biomedical sciences, and life sciences sectors. More information about this communications platform is available at https://www.BioMedWire.com, with full terms of use and disclaimers accessible at https://www.BioMedWire.com/Disclaimer.
The advancement of abuse-deterrent technologies represents a significant area of pharmaceutical development with potential public health benefits. As regulatory pathways evolve for these products, companies like Nutriband contribute to the landscape of pain management options designed with safety considerations in mind. The progress reported in the shareholder update indicates steady advancement toward key regulatory milestones for AVERSA Fentanyl.
